Last reviewed · How we verify
Recombinant influenza hemagglutinin
Recombinant influenza hemagglutinin stimulates the immune system to produce antibodies and cellular immunity against influenza virus.
Recombinant influenza hemagglutinin stimulates the immune system to produce antibodies and cellular immunity against influenza virus. Used for Influenza prevention.
At a glance
| Generic name | Recombinant influenza hemagglutinin |
|---|---|
| Also known as | Panblok-H7 |
| Sponsor | Vaxine Pty Ltd |
| Drug class | Recombinant protein vaccine |
| Target | Influenza hemagglutinin |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This vaccine antigen is produced through recombinant DNA technology and presents the hemagglutinin protein from influenza virus to the immune system. Hemagglutinin is the major surface antigen that the body recognizes and mounts an immune response against. By exposing the immune system to this purified recombinant protein, the vaccine induces both humoral (antibody) and cell-mediated immune responses that protect against subsequent influenza infection.
Approved indications
- Influenza prevention
Common side effects
- Injection site reactions (pain, redness, swelling)
- Myalgia
- Headache
- Fatigue
Key clinical trials
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study (PHASE4)
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects (PHASE1)
- Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above (PHASE1)
- Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age (PHASE1)
- Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant influenza hemagglutinin CI brief — competitive landscape report
- Recombinant influenza hemagglutinin updates RSS · CI watch RSS
- Vaxine Pty Ltd portfolio CI